Mankind Pharma growth over the years

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Compounded a year	1 yr	3 yr
Revenue	+17.0%	+17.7%
EBITDA	+19.9%	+23.9%
Net Income	−3.6%	+14.0%
EPS (adj.)	−3.7%	+14.3%
Total Assets	+1.2%	+42.4%
Total Equity	+13.7%	+29.5%
Free Cash Flow	+25.9%	+34.4%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MANKIND₹2,490.00

Mankind Pharma Ltd.

· Pharma & Health

₹ CrorePeersSUNPHARMA CIPLA TORNTPHARM LAURUSLABS BIOCON ALKEM LUPIN GLENMARKMcap ₹1.03L Cr

Annuals · FY-end closes

Compounded Growth Annuals · CAGR %	1Y CAGR	3Y CAGR
Revenue	+17.0	+17.7
EBITDA	+19.9	+23.9
Net Income	-3.6	+14.0
EPS (adj.)	-3.7	+14.3
Total Assets	+1.2	+42.4
Total Equity	+13.7	+29.5
Free Cash Flow	+25.9	+34.4

CAGR from filed annuals — needs positive start & end values.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.